ARDX · Company research
Ardelyx, Inc. (ARDX): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
39records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| Robbins LLP Urges ARDX Stockholders to Contact the Firm for Information About the Securities Class Action Against Ardelyx, Inc. | A securities class action has been filed against Ardelyx, Inc. (NASDAQ: ARDX) alleging the company misled investors about its commercial performance and growth prospects for its drug products IBSRELA and XPHOZAH. The lawsuit covers purchases between January 13, 2025 and August 6, 2026. On August 6, 2026, Ardelyx reduced its full-year 2026 IBSRELA revenue guidance and withdrew long-term XPHOZAH guidance due to increased payer access barriers, causing the stock to drop 18% in one day from $4.87 to $4.00 per share. | View source ↗ | GlobeNewswire Inc. | Oct 19, 2026 | bearish | -1 | 1 |
| ARDX Investors Have Opportunity to Lead Ardelyx, Inc. Securities Fraud Lawsuit with SBS Law | Schall, Brown & Schwartz LLP has filed a class action lawsuit against Ardelyx, Inc. for alleged securities violations. The lawsuit claims the company made false and misleading statements regarding reimbursement barriers and patient access issues for its drugs XPHOZAH and IBSRELA, which impacted commercial performance. The class period spans January 13, 2025 to August 6, 2026, with a deadline of November 16, 2026 for shareholders to participate. | View source ↗ | GlobeNewswire Inc. | Oct 16, 2026 | bearish | -1 | 1 |
| ARDX Investors Have Opportunity to Lead Ardelyx, Inc. Securities Fraud Lawsuit with SBS Law | Schall, Brown & Schwartz LLP has filed a class action lawsuit against Ardelyx, Inc. for alleged securities violations. The lawsuit claims the company made false and misleading statements regarding reimbursement barriers and patient access issues for its drugs XPHOZAH and IBSRELA, which impacted commercial performance. The class period spans January 13, 2025 to August 6, 2026, with a deadline of November 16, 2026 for shareholders to participate. | View source ↗ | GlobeNewswire Inc. | Oct 16, 2026 | bearish | -1 | 1 |
| Bronstein, Gewirtz & Grossman LLC Urges Ardelyx, Inc. Investors to Act: Class Action Filed Alleging Investor Harm | A class action lawsuit has been filed against Ardelyx, Inc. for alleged securities fraud. The complaint alleges that the company made false and misleading statements regarding payer access barriers, prior authorization requirements, and commercial performance of its drugs XPHOZAH and IBSRELA during the period from January 13, 2025 to August 6, 2026. Investors have until November 16, 2026 to request lead plaintiff status. | View source ↗ | GlobeNewswire Inc. | Oct 15, 2026 | bearish | -1 | 1 |
| Bronstein, Gewirtz & Grossman LLC Urges Ardelyx, Inc. Investors to Act: Class Action Filed Alleging Investor Harm | A class action lawsuit has been filed against Ardelyx, Inc. for alleged securities fraud. The complaint alleges that the company made false and misleading statements regarding payer access barriers, prior authorization requirements, and commercial performance of its drugs XPHOZAH and IBSRELA during the period from January 13, 2025 to August 6, 2026. Investors have until November 16, 2026 to request lead plaintiff status. | View source ↗ | GlobeNewswire Inc. | Oct 15, 2026 | bearish | -1 | 1 |
| Bronstein, Gewirtz & Grossman LLC Urges Ardelyx, Inc. Investors to Act: Class Action Filed Alleging Investor Harm | A class action lawsuit has been filed against Ardelyx, Inc. for alleged securities fraud. The complaint alleges that the company made false and misleading statements regarding payer access barriers, prior authorization requirements, and commercial performance of its drugs XPHOZAH and IBSRELA during the period from January 13, 2025 to August 6, 2026. Investors have until November 16, 2026 to request lead plaintiff status. | View source ↗ | GlobeNewswire Inc. | Oct 15, 2026 | bearish | -1 | 1 |
| ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Ardelyx, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ARDX | Rosen Law Firm is urging investors who purchased Ardelyx common stock between January 13, 2025 and August 6, 2026 to join a securities class action lawsuit. The lawsuit alleges that Ardelyx provided misleading statements about its commercial performance and concealed material facts regarding reimbursement barriers and access issues for its drugs XPHOZAH and IBSRELA, resulting in investor damages. | View source ↗ | GlobeNewswire Inc. | Oct 14, 2026 | bearish | -1 | 1 |
| ARDX DEADLINE: Levi & Korsinsky Reminds Ardelyx, Inc. Investors of Upcoming Securities Class Action Deadline - Morningstar | ARDX DEADLINE: Levi & Korsinsky Reminds Ardelyx, Inc. Investors of Upcoming Securities Class Action Deadline Morningstar | View source ↗ | Morningstar | Oct 14, 2026 | neutral | 0 | 0.6 |
| A study of 470 adults with irritable bowel syndrome and constipation found fewer care visits after treatment began. - Stock Titan | A study of 470 adults with irritable bowel syndrome and constipation found fewer care visits after treatment began. Stock Titan | View source ↗ | Stock Titan | Oct 12, 2026 | neutral | 0 | 0.6 |
| New Strong Sell Stocks for October 9th | Zacks has added three stocks to its Strong Sell list: Accendra Health (ACH), Ardelyx (ARDX), and Draganfly (DPRO). All three companies have experienced significant downward revisions to their earnings estimates over the past 60 days, with ACH seeing a 109.4% downward revision, ARDX a 25% revision, and DPRO a 59.6% revision. | View source ↗ | Zacks Investment Research | Oct 9, 2026 | bearish | -1 | 1 |
| New Strong Sell Stocks for October 9th | Zacks has added three stocks to its Strong Sell list: Accendra Health (ACH), Ardelyx (ARDX), and Draganfly (DPRO). All three companies have experienced significant downward revisions to their earnings estimates over the past 60 days, with ACH seeing a 109.4% downward revision, ARDX a 25% revision, and DPRO a 59.6% revision. | View source ↗ | Zacks Investment Research | Oct 9, 2026 | bearish | -1 | 1 |
| ROSEN, LEADING TRIAL ATTORNEYS, Encourages Ardelyx, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ARDX | Rosen Law Firm is urging investors who purchased Ardelyx common stock between January 13, 2025 and August 6, 2026 to join a securities class action lawsuit. The lawsuit alleges that Ardelyx provided misleading statements about its commercial performance and concealed material facts regarding reimbursement barriers and access issues for its drugs XPHOZAH and IBSRELA, resulting in investor damages. | View source ↗ | GlobeNewswire Inc. | Oct 9, 2026 | bearish | -1 | 1 |
| ROSEN, LEADING TRIAL ATTORNEYS, Encourages Ardelyx, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ARDX | Rosen Law Firm is urging investors who purchased Ardelyx common stock between January 13, 2025 and August 6, 2026 to join a securities class action lawsuit. The lawsuit alleges that Ardelyx provided misleading statements about its commercial performance and concealed material facts regarding reimbursement barriers and access issues for its drugs XPHOZAH and IBSRELA, resulting in investor damages. | View source ↗ | GlobeNewswire Inc. | Oct 9, 2026 | bearish | -1 | 1 |
| ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Hims & Hers Health, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - HIMS | Rosen Law Firm has filed securities class action lawsuits against Hims & Hers Health, Duolingo, and Ardelyx. The Hims lawsuit alleges the company made false statements regarding data privacy practices, prescription charging procedures, and failed to disclose regulatory scrutiny and potential penalties. Investors who purchased securities during specified class periods are encouraged to join the litigation before the November 2, 2026 lead plaintiff deadline. | View source ↗ | GlobeNewswire Inc. | Oct 9, 2026 | bearish | -1 | 1 |
| ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Hims & Hers Health, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - HIMS | Rosen Law Firm has filed securities class action lawsuits against Hims & Hers Health, Duolingo, and Ardelyx. The Hims lawsuit alleges the company made false statements regarding data privacy practices, prescription charging procedures, and failed to disclose regulatory scrutiny and potential penalties. Investors who purchased securities during specified class periods are encouraged to join the litigation before the November 2, 2026 lead plaintiff deadline. | View source ↗ | GlobeNewswire Inc. | Oct 9, 2026 | bearish | -1 | 1 |
| Ardelyx, Inc. (ARDX) Stock Price, News, Quote & History - Yahoo! Finance Canada | Ardelyx, Inc. (ARDX) Stock Price, News, Quote & History Yahoo! Finance Canada | View source ↗ | Yahoo! Finance Canada | Oct 8, 2026 | neutral | 0 | 0.6 |
| ARDX Stock Jumps Over 5% Overnight As Director Loads Up In Vote Of Confidence For Flagship Constipation Drug - Stocktwits | ARDX Stock Jumps Over 5% Overnight As Director Loads Up In Vote Of Confidence For Flagship Constipation Drug Stocktwits | View source ↗ | Stocktwits | Oct 8, 2026 | neutral | 0 | 0.6 |
| New Strong Sell Stocks for October 7th | Zacks has added three stocks to its Strong Sell list today: Ardelyx (ARDX), a biopharmaceutical company with a 53.9% downward earnings revision; Southwest Airlines (LUV), a passenger airline with a 4.1% downward earnings revision; and Collegium Pharmaceutical (COLL), a specialty pharmaceutical company with a nearly 3% downward earnings revision over the last 60 days. | View source ↗ | Zacks Investment Research | Oct 7, 2026 | bearish | -1 | 1 |
| New Strong Sell Stocks for October 7th | Zacks has added three stocks to its Strong Sell list today: Ardelyx (ARDX), a biopharmaceutical company with a 53.9% downward earnings revision; Southwest Airlines (LUV), a passenger airline with a 4.1% downward earnings revision; and Collegium Pharmaceutical (COLL), a specialty pharmaceutical company with a nearly 3% downward earnings revision over the last 60 days. | View source ↗ | Zacks Investment Research | Oct 7, 2026 | bearish | -1 | 1 |
| ARDX Stock Is Down Pre-Market After Q4 Earnings Miss, So Why Did This Firm Just Hike Price Target By 80%? - Stocktwits | ARDX Stock Is Down Pre-Market After Q4 Earnings Miss, So Why Did This Firm Just Hike Price Target By 80%? Stocktwits | View source ↗ | Stocktwits | Oct 7, 2026 | neutral | 0 | 0.6 |
| Lead Plaintiff Deadlines in Shareholder Class Action Lawsuits Against Baidu, Inc. (BIDU), Ardelyx, Inc. (ARDX), and Better Home & Finance Holding Company (BETR) Announced by Holzer & Holzer, LLC | Holzer & Holzer, LLC announced lead plaintiff deadlines for multiple shareholder class action lawsuits against Baidu, Ardelyx, and Better Home & Finance Holding Company. The lawsuits allege materially false and misleading statements regarding business operations and financial projections. Investors who purchased shares during specified periods and suffered losses are encouraged to seek legal representation. | View source ↗ | GlobeNewswire Inc. | Oct 6, 2026 | bearish | -1 | 1 |
| Lead Plaintiff Deadlines in Shareholder Class Action Lawsuits Against Baidu, Inc. (BIDU), Ardelyx, Inc. (ARDX), and Better Home & Finance Holding Company (BETR) Announced by Holzer & Holzer, LLC | Holzer & Holzer, LLC announced lead plaintiff deadlines for multiple shareholder class action lawsuits against Baidu, Ardelyx, and Better Home & Finance Holding Company. The lawsuits allege materially false and misleading statements regarding business operations and financial projections. Investors who purchased shares during specified periods and suffered losses are encouraged to seek legal representation. | View source ↗ | GlobeNewswire Inc. | Oct 6, 2026 | bearish | -1 | 1 |
| ROSEN, SKILLED INVESTOR COUNSEL, Encourages Ardelyx, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ARDX | Rosen Law Firm is notifying investors in Ardelyx, Inc. who purchased stock between January 13, 2025 and August 6, 2026 about a securities class action lawsuit. The complaint alleges that Ardelyx made materially false and misleading statements regarding commercial performance and growth prospects for its drugs XPHOZAH and IBSRELA, while concealing information about payer access barriers, prior authorization requirements, and step edit requirements that hindered patient access. Investors have until November 16, 2026 to serve as lead plaintiff. | View source ↗ | GlobeNewswire Inc. | Oct 5, 2026 | bearish | -1 | 1 |
| ROSEN, SKILLED INVESTOR COUNSEL, Encourages Ardelyx, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ARDX | Rosen Law Firm is notifying investors in Ardelyx, Inc. who purchased stock between January 13, 2025 and August 6, 2026 about a securities class action lawsuit. The complaint alleges that Ardelyx made materially false and misleading statements regarding commercial performance and growth prospects for its drugs XPHOZAH and IBSRELA, while concealing information about payer access barriers, prior authorization requirements, and step edit requirements that hindered patient access. Investors have until November 16, 2026 to serve as lead plaintiff. | View source ↗ | GlobeNewswire Inc. | Oct 5, 2026 | bearish | -1 | 1 |
| ARDX Investor Alert: Ardelyx, Inc. Securities Class Action Notice – Contact Levi & Korsinsky - GlobeNewswire | ARDX Investor Alert: Ardelyx, Inc. Securities Class Action Notice – Contact Levi & Korsinsky GlobeNewswire | View source ↗ | GlobeNewswire | Oct 5, 2026 | neutral | 0 | 0.6 |
| Bronstein, Gewirtz & Grossman LLC Urges Ardelyx, Inc. Investors to Act: Class Action Filed Alleging Investor Harm | A class action lawsuit has been filed against Ardelyx, Inc. alleging that the company made false and misleading statements regarding payer access barriers and reimbursement issues affecting its drugs XPHOZAH and IBSRELA. The lawsuit covers investors who purchased Ardelyx securities between January 13, 2025 and August 6, 2026. The lead plaintiff deadline is November 16, 2026. | View source ↗ | GlobeNewswire Inc. | Oct 5, 2026 | bearish | -1 | 1 |
| Many of about 550,000 U.S. dialysis patients have high blood phosphate. Ardelyx will present three studies. - Stock Titan | Many of about 550,000 U.S. dialysis patients have high blood phosphate. Ardelyx will present three studies. Stock Titan | View source ↗ | Stock Titan | Oct 5, 2026 | neutral | 0 | 0.6 |
| Ardelyx (NasdaqGM:ARDX) Stock Forecast & Analyst Predictions - Simply Wall Street | Ardelyx (NasdaqGM:ARDX) Stock Forecast & Analyst Predictions Simply Wall Street | View source ↗ | Simply Wall Street | Oct 5, 2026 | neutral | 0 | 0.6 |
| ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Ardelyx, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ARDX | Rosen Law Firm is reminding investors who purchased Ardelyx common stock between January 13, 2025 and August 6, 2026 of an important November 16, 2026 lead plaintiff deadline in an ongoing securities class action. The lawsuit alleges that Ardelyx provided misleading statements about its commercial performance and concealed material facts regarding reimbursement barriers and access issues for its drugs XPHOZAH and IBSRELA. | View source ↗ | GlobeNewswire Inc. | Oct 2, 2026 | bearish | -1 | 1 |
| ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Ardelyx, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ARDX | Rosen Law Firm is reminding investors who purchased Ardelyx common stock between January 13, 2025 and August 6, 2026 of an important November 16, 2026 lead plaintiff deadline in an ongoing securities class action. The lawsuit alleges that Ardelyx provided misleading statements about its commercial performance and concealed material facts regarding reimbursement barriers and access issues for its drugs XPHOZAH and IBSRELA. | View source ↗ | GlobeNewswire Inc. | Oct 2, 2026 | bearish | -1 | 1 |
| A podcast on gut disorders wins gold at the PM360 awards - Stock Titan | A podcast on gut disorders wins gold at the PM360 awards Stock Titan | View source ↗ | Stock Titan | Sep 30, 2026 | neutral | 0 | 0.6 |
| ARDELYX INC (ARDX) Stock Chart - ChartMill | ARDELYX INC (ARDX) Stock Chart ChartMill | View source ↗ | ChartMill | Sep 26, 2026 | neutral | 0 | 0.6 |
| Ardelyx (ARDX) Securities Investigation Notice - Levi & Korsinsky - PR Newswire | Ardelyx (ARDX) Securities Investigation Notice - Levi & Korsinsky PR Newswire | View source ↗ | PR Newswire | Aug 20, 2026 | neutral | 0 | 0.6 |
| ARDX Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Ardelyx (ARDX) - WBOC TV | ARDX Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Ardelyx (ARDX) WBOC TV | View source ↗ | WBOC TV | Aug 17, 2026 | neutral | 0 | 0.6 |
| Ardelyx Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Ardelyx (ARDX) - PR Newswire | Ardelyx Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Ardelyx (ARDX) PR Newswire | View source ↗ | PR Newswire | Aug 13, 2026 | neutral | 0 | 0.6 |
| Ardelyx (ARDX) Stock Slides As Payer Friction Clouds Growth Path - Simply Wall Street | Ardelyx (ARDX) Stock Slides As Payer Friction Clouds Growth Path Simply Wall Street | View source ↗ | Simply Wall Street | Aug 8, 2026 | neutral | 0 | 0.6 |
| $ARDX stock is down 16% today. Here's what we see in our data. - Quiver Quantitative | $ARDX stock is down 16% today. Here's what we see in our data. Quiver Quantitative | View source ↗ | Quiver Quantitative | Aug 7, 2026 | neutral | 0 | 0.6 |
| Ardelyx (ARDX) Posts Record Revenue, Is The Stock Still 70% Undervalued? - Yahoo Finance | Ardelyx (ARDX) Posts Record Revenue, Is The Stock Still 70% Undervalued? Yahoo Finance | View source ↗ | Yahoo Finance | Aug 7, 2026 | neutral | 0 | 0.6 |
| Ardelyx (ARDX) Stock Valuation Check After Recent Share Price Volatility - Yahoo Finance | Ardelyx (ARDX) Stock Valuation Check After Recent Share Price Volatility Yahoo Finance | View source ↗ | Yahoo Finance | Jun 12, 2026 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.